Interleukin-2

Clinicians treating patients with tumor-infiltrating lymphocytes should closely monitor toxicities associated with interleukin-2 and halt administration of the drug if necessary, according to the first guidelines regarding the therapy.

Steven A. Rosenberg, MD, PhD, FAACR, will receive this year’s Pezcoller Foundation-American Association of Cancer Research International Award for Extraordinary Achievement in Cancer Research.

Ryan Cassaday, MD, associate professor of hematology at University of Washington, discussed new platforms for cellular immunotherapy and the Devillier presentation of natural killer (NK) cells in a therapeutic setting presented at the ASH Annual Meeting and Exposition.

The FDA granted breakthrough therapy designation to bempegaldesleukin in combination with nivolumab for initial treatment of unresectable or metastatic melanoma.